N-Butyl-N'-dodecylurea | 118389-04-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: N-Butyl-N'-dodecylurea
• 英文别名: 1-butyl-3-dodecylurea
• CAS: 118389-04-1
• 化学式: C₁₇H₃₆N₂O
• 分子量: 284.5
• InChiKey: BUIQXSYFILIPAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  20
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  异氰酸正丁酯 、 十二烷基伯胺 生成 N-Butyl-N'-dodecylurea
  参考文献：
  名称：

  MUNTEAN, IOAN;HERDAN, JEAN MICHEL;VALEANU, GABRIELA, REV. ROUM. CHIM., 33,(1988) N 5, C. 467-471

  摘要：

  DOI：

文献信息

• INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION
  申请人：Hammock D. Bruce

  公开号：US20070117782A1

  公开（公告）日：2007-05-24

  The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R 1 -R 4 is hydrogen, R 2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R 4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R 1 and R 3 is each independently C 1 -C 20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

  本发明提供了一些化合物，用于治疗高血压的治疗应用中，抑制环氧水解酶。实施本发明的优选化合物类别具有由式1所示的结构，其中Z为氧或硫，W为碳、磷或硫，X和Y各自独立地为氮、氧或硫，而X还可以是碳，R1-R4中至少有一个是氢，当X为氮时，R2为氢，但当X为硫或氧时，R2不存在，当Y为氮时，R4为氢，但当Y为硫或氧时，R4不存在，而R1和R3各自独立地为C1-C20取代或未取代的烷基、环烷基、芳基、酰基或杂环基。
• MUNTEAN, IOAN;HERDAN, JEAN MICHEL;VALEANU, GABRIELA, REV. ROUM. CHIM., 33,(1988) N 5, C. 467-471
  作者：MUNTEAN, IOAN、HERDAN, JEAN MICHEL、VALEANU, GABRIELA

  DOI：——

  日期：——
• JPH03269042A
  申请人：——

  公开号：JPH03269042A

  公开（公告）日：1991-11-29
• JPH048752A
  申请人：——

  公开号：JPH048752A

  公开（公告）日：1992-01-13
• INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION
  申请人：Kroetz Deanna L.

  公开号：US20110245331A1

  公开（公告）日：2011-10-06

  The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R 1 -R 4 is hydrogen, R 2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R 4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R 1 and R 3 is each independently C 1 -C 20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.